Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11221793 | 0.80 | PSIP1 (0.42) | ALDH1A1MAPTGAARAB9A | |
| SCHEMBL1828201 | 0.79 | CA1 (0.47) | LMNAMAPTMEN1KMT2AGAA | |
| SCHEMBL5505800 | 0.79 | ALDH1A1 (0.39) | LMNASMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL10766553 | 0.79 | VCAM1 (0.46) | LMNASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL6319405 | 0.79 | CA12 (0.50) | LMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL29119590 | 0.79 | CA12 (0.36) | — | |
| SCHEMBL18660576 | 0.77 | PSEN1 (0.30) | — | |
| SCHEMBL9450866 | 0.77 | PSEN1 (0.30) | — | |
| SCHEMBL1448262 | 0.77 | SMN1; SMN2 (0.37) | LMNAG6PDIDESMN1; SMN2PTGS2 | |
| SCHEMBL941266 | 0.77 | G6PD (0.37) | LMNAG6PDIDESMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| CN-113880762-B | Triacylamine derivatives containing 1,8-naphthalimide as well as preparation method and application thereof | 河北农业大学 | 2023-02-21 | — | — | CN | claimed |
| CN-115557895-A | Pyrazole derivative and preparation method and application thereof | 贵州大学 | 2023-01-03 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| CN-113880762-A | 1, 8-naphthalimide-containing triacylamine derivatives, and preparation method and application thereof | 河北农业大学 | 2022-01-04 | — | — | CN | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| WO-2001004117-A1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| US-6083879-A | Herbicidal benzoylisothiazoles | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-04 | — | — | US | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| EP-0897384-A1 | HERBICIDAL BENZOYLISOTHIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-24 | — | — | EP | claimed |
| WO-1997038987-A1 | HERBICIDAL BENZOYLISOTHIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-23 | — | — | WO | claimed |
| US-4978362-A | Thermoplastic resin composition containing polyalkyleneoxy-substituted azo coloring agents having trifluoromethyl substituents | MILLIKEN RESEARCH CORPORATION (US) | 1990-12-18 | — | — | US | claimed |
| US-4751254-A | COLORING POLURETHANES USING POLYALKOXYTRIFLUOROANILINE COMPOUNDS | MILLIKEN RESEARCH CORPORATION (US) | 1988-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | LMNA 2009/4885G6PD 4219/4885IDE 3736/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | LMNA 4157/4885G6PD 1960/4885IDE 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.